drugset / Trial / NCT07032714
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Phase 1
Recruiting
25 enrolled
Massachusetts General Hospital
Celgene Corporation · collabJanssen Research and Development LLC · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to test the effects of the drugs on cancer. Cohort A will receive talquetamab + dexamethasone, then mezigdomide + talquetamab,+ dexamethasone. After Cohort A, Cohort B will evaluate mezigdomide + dexamethasone followed by step-up dosing of talquetamab (mezigdomide + talquetamab,+ dexamethasone).
Timeline
- Start
- 2025-12-19
- Primary completion
- 2027-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mezigdomide | Small molecule | — | Oral |
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |
| Background | Dexamethasone | Small molecule | — | Oral |